Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS Involvement.
Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS Involvement. Blood Adv. 2025 May 07.
PMID: 40334068
Real World Outcomes for Young Adult Patients Receiving CD19 CAR T-cell Therapy.
Real World Outcomes for Young Adult Patients Receiving CD19 CAR T-cell Therapy. Blood Adv. 2025 Mar 24.
PMID: 40127395
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL. Blood Adv. 2024 Dec 10; 8(23):6139-6147.
PMID: 39093952
Somatic co-alteration signatures are prognostic in high-grade TP53-mutated myeloid neoplasms.
Somatic co-alteration signatures are prognostic in high-grade TP53-mutated myeloid neoplasms. Br J Haematol. 2025 Apr; 206(4):1103-1108.
PMID: 39551719
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation. Haematologica. 2024 Nov 01; 109(11):3739-3744.
PMID: 38618681
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. J Clin Oncol. 2025 Feb 10; 43(5):558-566.
PMID: 39418622
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors.
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239.
PMID: 36655425
Multicenter analysis of immunosuppressive medications on the risk of malignancy following adult solid organ transplantation.
Multicenter analysis of immunosuppressive medications on the risk of malignancy following adult solid organ transplantation. Front Oncol. 2023; 13:1146002.
PMID: 37397376
Clinical guideline variability in the diagnosis of hereditary hematopoietic malignancy syndromes.
Clinical guideline variability in the diagnosis of hereditary hematopoietic malignancy syndromes. Leuk Lymphoma. 2023 09; 64(9):1562-1565.
PMID: 37294121
Clinical considerations at the intersection of hematopoietic cell transplantation and hereditary hematopoietic malignancy.
Clinical considerations at the intersection of hematopoietic cell transplantation and hereditary hematopoietic malignancy. Front Oncol. 2023; 13:1180439.
PMID: 37251919